Arrowhead Pharmaceuticals (ARWR) Stock Forecast: StockMap's 2-Week Call
ARWR stock forecast: StockMap's model leans Underperform on Arrowhead Pharmaceuticals for the two weeks after the Nov 13 close, toward ARWR trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 2 of 3 two-week windows on ARWR since Sep 24; by chance, a call on the same dates was right 51% of the time.
Arrowhead Pharmaceuticals last closed at $47.78, +1.34% on the session.
Against the IVW growth benchmark the position is +2.25% over the forecast window.
Arrowhead Pharmaceuticals' market cap is $6.75B as of November 13, 2026.
Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -48 (too close to call).
Where ARWR sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 1 bullish and 14 bearish.
Agreement across those insights is 93%.
23 daily calls for ARWR so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Arrowhead Pharmaceuticals in the 16th percentile on return on equity, where 100 is best.
Arrowhead Pharmaceuticals is classified under Health Care / Biotechnology.
StockMap tracks Arrowhead Pharmaceuticals as the 42nd largest of the 391 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 186 Moderate Underperform, 157 Neutral, 33 Strong Underperform and 15 Moderate Outperform.
On that composite Arrowhead Pharmaceuticals ranks 347th of 391 in the group, against a group median of -0.24.